Browsing “LegislativeLegislative | EVERSANA”

Building a Service Offering from the Research Lab to the Patient’s Home

A Conversation with Pharmaceutical Commerce & Jim Lang, Chief Executive Officer, EVERSANA Not quite a year ago, an assemblage of pharma service providers came into being as EVERSANA. Funded by two private equity firms with a background in healthcare—Water Street Healthcare Partners and JLL Partners, there were six acquisitions at the time: Dohmen Life Science […]

Insights from AMCP 2019

EVERSANA attended (and sponsored) The Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting. If you missed the conference, here are a few key takeaways from our colleagues who attended: 1) Federal and State Legislature Update Increases in federal and state policies are putting more pressure on drug prices The possible removal […]

Could CMS Policies Impact Investments in CAR T-cell Therapies and Other Innovative Treatments?

Clinical pathways that include CAR T-cell therapy as an option must integrate appropriate guidance on its use and settings of care.

How Could Policy Changes to Protected Classes Impact Part D Access and Contracting?

(Content Updated 5/17) CMS Protected Class Rule Finalized, Slightly Loosened for Biopharma Following CMS’ 2018 proposed rule allowing for new protected class exceptions and a comment period for stakeholders through the beginning of this year, CMS has released a final rule addressing the Medicare Part D Protected Classes. The proposed rule allowed plans to restrict […]